VANDA PHARMACEUTICALS INC. Cost of Goods Sold (Deprecated 2018-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) reported Cost of Goods Sold (Deprecated 2018-01-31) of $6.99 million for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2016-11-03
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2016-09-30 was $6.99M, a 7.37% increase year-over-year.
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2016-06-30 was $6.49M, a 12.63% increase year-over-year.
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2016-03-31 was $5.96M, a 18.76% increase year-over-year.
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2015-12-31 was $6.17M, a 804.84% increase year-over-year.
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $23.46M, a 1382.12% increase from fiscal 2014.
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $1.58M.
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2012 was $129.00K.
- VANDA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2010 was $2.89M, a 50.97% increase from fiscal 2009.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2016-09-30 | $6.99M 10-Q · filed 2016-11-03 | $13.48M derived: sum of 2 quarters · filed 2016-11-03 | $19.44M 10-Q · filed 2016-11-03 | $25.61M derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-06-30 | $6.49M 10-Q · filed 2016-07-28 | $12.45M 10-Q · filed 2016-07-28 | $18.62M derived: sum of 3 quarters · filed 2016-07-28 | $25.13M derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-03-31 | $5.96M 10-Q · filed 2016-05-05 | $12.13M derived: sum of 2 quarters · filed 2016-05-05 | $18.64M derived: sum of 3 quarters · filed 2016-11-03 | $24.40M derived: sum of 4 quarters · filed 2016-11-03 |
| 2015-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $12.68M derived: sum of 2 quarters · filed 2016-11-03 | $18.45M derived: sum of 3 quarters · filed 2016-11-03 | $23.46M 10-K · filed 2016-02-12 |
| 2015-09-30 | $6.51M 10-Q · filed 2016-11-03 | $12.28M derived: sum of 2 quarters · filed 2016-11-03 | $17.29M 10-Q · filed 2016-11-03 | $17.97M derived: sum of 4 quarters · filed 2016-11-03 |
| 2015-06-30 | $5.77M 10-Q · filed 2016-07-28 | $10.78M 10-Q · filed 2016-07-28 | $11.46M derived: sum of 3 quarters · filed 2016-07-28 | $12.17M derived: sum of 4 quarters · filed 2016-07-28 |
| 2015-03-31 | $5.01M 10-Q · filed 2016-05-05 | $5.70M derived: sum of 2 quarters · filed 2016-05-05 | $6.40M derived: sum of 3 quarters · filed 2016-05-05 | $6.60M derived: sum of 4 quarters · filed 2016-05-05 |
| 2014-12-31 | $682.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $1.39M derived: sum of 2 quarters · filed 2016-02-12 | $1.58M derived: sum of 3 quarters · filed 2016-02-12 | $1.58M 10-K · filed 2016-02-12 |
| 2014-09-30 | $703.00K 10-Q · filed 2015-11-04 | $901.00K derived: sum of 2 quarters · filed 2015-11-04 | $901.00K 10-Q · filed 2015-11-04 | |
| 2014-06-30 | $198.00K 10-Q · filed 2015-07-31 | $198.00K 10-Q · filed 2015-07-31 | ||
| 2012-12-31 | $129.00K 10-K · filed 2015-03-13 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $0.00 derived: sum of 2 quarters · filed 2013-02-26 | $1.52M derived: sum of 3 quarters · filed 2013-02-26 | $2.89M 10-K · filed 2013-02-26 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $1.52M derived: sum of 2 quarters · filed 2011-11-07 | $2.89M 10-Q · filed 2011-11-07 | |
| 2010-06-30 | $1.52M 10-Q · filed 2011-08-05 | $2.89M 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $1.92M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |